Moshe Rogosnitzky is a research scientist, innovator and inventor of major medical breakthroughs, and consultant to oncology specialists, patients and companies. His extraordinary career has spanned multiple disciplines and has produced ground-breaking cancer, autoimmune and chronic disease treatments. His belief that medicine and science should deliver rapid and tangible benefits to the patient has been the driving force behind all his accomplishments.
Research Scientist
Rogosnitzky has a long history of highly rewarding collaborations and joint research projects with leading academic institutions. He has published significant medical research in multiple fields including autoimmune disease (Crohn’s Disease), cancer (breast, prostate, skin, liver and pancreatic cancer), abdominal surgery, hemostasis, and eye disease. He has served as peer reviewer for several medical journals.
Medical Innovator
His pioneering work has resulted in the development of new treatments for various types of cancer. His highly promising treatment for Crohn's disease using Low Dose Naltrexone (LDN) has completed Phase I and II trials, and has been licensed to Cytocom Inc. (soon entering Phase III trials). He has also developed the first-ever non-surgical treatment for a common eye condition known as pterygium. An innovator in both targeted and off-label uses of medications, Rogosnitzky holds intellectual property rights in numerous fields.
Consultant
Rogosnitzky established a personalized-medicine consultancy in 1999, focusing on treatment of Stage IV cancer. His multi-discipline expertise allows him to consult to specialist oncology panels. He has served on five Champions Oncology VIP Expert Opinion Panels (pancreatic cancer, lung cancer, esophageal cancer, metastatic melanoma, and sarcoma). He is regularly invited to lecture at conferences in North America, Europe and Asia, and has guest lectured at the Israeli Government Ministry of Health.
Philanthropist and Teacher
In 2006 Moshe co-founded the non-profit MedInsight® Research Institute. As Research Director, he oversees the synthesis of published medical research into comprehensive, consumer-friendly summaries. In 2009 Moshe founded We Fund The Cure®, a non-profit organization that has been at the forefront of facilitating research of new uses for existing drugs.
In 2014 Moshe founded the Center for Drug Repurposing at Ariel University.
Dipyridamole Eye Drops
Cureiosity®